Race influences warfarin dose changes associated with genetic factors

Blood

Volumn 126, Issue 4, 2015, Pages 539-545

  Limdi, Nita A ^a   Brown, Todd M ^b   Yan, Qi ^c   Thigpen, Jonathan L ^d   Shendre, Aditi ^e   Liu, Nianjun ^e   Hill, Charles E ^f   Arnett, Donna K ^e   Beasley, T Mark ^e  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d NOTRE DAME OF MARYLAND UNIVERSITY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C9; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYP4F2 PROTEIN, HUMAN; CYTOCHROME P450; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BODY SURFACE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CYP4F2 GENE; DRUG USE; EUROPEAN AMERICAN; FEMALE; GENE; GENETIC VARIABILITY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; VKORC1 GENE; ALGORITHM; ANCESTRY GROUP; CAUCASIAN; CHRONIC KIDNEY FAILURE; DOSE RESPONSE; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MIDDLE AGED; PATHOLOGY; PHARMACOGENETICS; PROGNOSIS; REGRESSION ANALYSIS; VENOUS THROMBOEMBOLISM;

AFRICAN AMERICANS; ALGORITHMS; ANTICOAGULANTS; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; VENOUS THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84938095470     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-627042     Document Type: Article

References (39)

1. Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010;87(4):459-464.
2. Cavallari LH, Perera M, Wadelius M, et al. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics. 2012;22(2):152-158.
3. Kimmel SE, Christie J, Kealey C, et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 2008;8(1):53-60.
4. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics. 2008;9(5):511-526.
5. Limdi NA, Beasley TM, Crowley MR, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics. 2008;9(10):1445-1458.
6. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008;83(2):312-321.
7. Perera MA, Gamazon E, Cavallari LH, et al. The missing association:sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther. 2011;89(3):408-415.
8. Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol. 2010;70(3):393-399.
9. Schelleman H, Chen J, Chen Z, et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther. 2008;84(3):332-339.
10. Schelleman H, Chen Z, Kealey C, et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther. 2007;81(5):742-747.
11. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326-331.
12. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010;87(5):572-578.
13. Cavallari LH, Vaynshteyn D, Freeman KM, et al. CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenet Genomics. 2013;23(4):228-231.
14. Klein TE, Altman RB, Eriksson N, et al International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-764.
15. Limdi NA, Wadelius M, Cavallari L, et al International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115(18):3827-3834.
16. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013;382(9894):790-796.
17. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy. 2004;24(10):1311-1316.
18. Flockhart DA, O'Kane D, Williams MS, et al; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10(2):139-150.
19. McClain MR, Palomaki GE, Piper M, Haddow JE. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med. 2008;10(2):89-98.
20. Pirmohamed M, Burnside G, Eriksson N, et al EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294-2303.
21. Kimmel SE, French B, Kasner SE, et al COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283-2293.
22. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009;20(4):912-921.
23. Daneshjou R, Gamazon ER, Burkley B, et al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood. 2014;124(14):2298-2305.
24. Suarez-Kurtz G, Botton MR. Pharmacogenomics of warfarin in populations of African descent. Br J Clin Pharmacol. 2013;75(2):334-346.
25. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010;56(5):823-831.
26. Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med. 2011;13(6):509-518.
27. Jonas DE, Evans JP, McLeod HL, et al. Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics. 2013;14(13):1593-1603.
28. Anderson JL, Horne BD, Stevens SM, et al Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116(22):2563-2570.
29. Borgman MP, Pendleton RC, McMillin GA, et al. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. Thromb Haemost. 2012;108(3):561-569.
30. Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012;125(16):1997-2005.
31. Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F; EU-PACT Study Group. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther. 2011;90(5):701-706.
32. Kimmel SE, French B, Geller NL; COAG Investigators. Genotype-guided dosing of vitamin K antagonists. N Engl J Med. 2014;370(18):1763-1764.
33. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690-1698.
34. Ramirez AH, Shi Y, Schildcrout JS, et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics. 2012;13(4):407-418.
35. Drozda K, Wong S, Patel SR, et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics. 2015;25(2):73-81.
36. Hernandez W, Gamazon ER, Aquino-Michaels K, et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J. 2014;14(3):223-228.
37. Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MA. Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis. 2011;46(2):147-150.
38. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010;87(4):445-451.
39. Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics. 2012;13(16):1925-1935.